Discontinued

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-08-01-2001, Volume 0, Issue 0

London/Sodertalje—AstraZeneca’s decision to drop Viozan (AR-C68397AA) for chronic obstructive pulmonary disease (COPD) could be GlaxoSmithKline’s gain.